On April 17, 2023 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported a poster presentation providing additional mechanistic insights into its Goldspire platform based on preclinical studies of its lead product candidate, IGV-001, for the treatment of glioblastoma (GBM) (Press release, Imvax, APR 17, 2023, View Source;utm_medium=rss&utm_campaign=imvax-presents-new-data-at-aacr-2023-supporting-the-mechanism-of-action-of-its-lead-program-igv-001-for-glioblastoma [SID1234630158]). These data are being presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Orlando, FL, running from April 14-19, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These new data provide us with deeper insights into the unique mechanism of our personalized immunotherapy platform, Goldspire, that combines whole-tumor derived cells with an antisense nucleotide in proprietary implanted chambers," said Mark A. Exley, Ph.D., Chief Scientific Officer. "The Goldspire platform is designed to induce a durable, broad-spectrum immune response against tumors, and additional studies like this one are key to furthering our understanding of both IGV-001 and our platform."
The data published in the AACR (Free AACR Whitepaper) poster presentation examined the effect on tumor cells of the Goldspire process, the release of subcellular immunogenic particles, their transit across the diffusible membrane of the implanted chambers and related immunological changes. IGV-001 was found to impose oxidative and endoplasmic reticulum stress onto GBM cells. Particle analysis confirmed that a human variant of IGV-001 prepared with human GBM cells produced particles that can efficiently diffuse through the membrane of the implanted chambers. Finally, the results indicated that lymph nodes through which IGV-001 drains are enriched in mature antigen-presenting cells and lymphoid effector cells.
The poster can be found on the Imvax website and the details for the presentation are below:
Title: ROS-dependent activation of immunogenic glioblastoma cell death & release of immunogenic particles by an autologous cell-based immunotherapeutic platform
Number: 1812
Timing: Monday, April 17, 2023, 9:00 AM – 12:30 PM
Presenter: Jenny Zilberberg, Ph.D.
About IGV-001
IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire immuno-oncology platform for solid tumors, which involves a unique approach to inducing a broad and durable immune response against tumors. Phase 1 studies showed that IGV-001 was safe and well tolerated, and a Phase 1b study in newly diagnosed GBM (ndGBM) patients also yielded several efficacy signals, including significant improvements in PFS, OS, radiographic evidence of tumor response and multiple biomarker changes that supported the presence of an immune response (Andrews DW, et al., Clin Cancer Res. 2021;27(7):1912-1922). In ten Stupp-eligible ndGBM patients in the highest dose cohort treated with IGV-001, median PFS was 17.1 months, compared with 6.5 months in historical standard-of-care (SOC) treatment, and median OS was 38.2 months, compared with 16.2 months in historical SOC. In March 2023, Imvax initiated a Phase 2b clinical trial of IGV-001 in ndGBM patients (NCT04485949).